Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) — ConCoVid-19  

COVID-19 Clinical Trial

Official title: Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19

Status Terminated

Clinical Trial Summary

Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus. Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection. With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion Primary objectives • Decrease overall mortality in patients within COVID disease Study design: This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care. Patient population: Patients with PCR confirmed COVID disease, age >18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days. Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year. Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months

Clinical Trial Description

Secondary (exploratory) objectives - Evaluate the effect of 300ml convP on hospital stay - Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 and 30 - Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80 - Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU - Evaluate the effect of 300ml plasma therapy on hospital days for patients admitted to the ICU within 24 hours after admission - Evaluate the impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways - Evaluate the difference in effect of convP on mortality in patients with a duration of symptoms < or > the median duration of symptoms in the study population - Evaluate the impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer - Safety of convP therapy - Evaluate the impact of covP on long-term lung function ;

Related Conditions & MeSH terms

• COVID-19

• NCT number: NCT04342182
• Study type: Interventional
• Source: Erasmus Medical Center
• Status: Terminated
• Phase: Phase 2/Phase 3
• Start date: April 8, 2020
• Completion date: September 30, 2020